Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays

17 de fevereiro de 2020 atualizado por: GlaxoSmithKline
The purpose of this study is to develop and characterize immunological assays on blood samples.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

99

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Brussels, Bélgica, 1070
        • GSK Investigational Site
      • Bruxelles, Bélgica, 1000
        • GSK Investigational Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Written informed consent obtained from the subject.
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • A male or female between, and including, 18 and 65 years of age at study start.
  • Evidence of chronic hepatitis B infection as per medical record.
  • Female subjects of non-childbearing potential may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.

In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:

Group A: Immune tolerant patients

  • Viral load: > 2x107 IU/mL of HBV DNA
  • HBeAg positive
  • Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
  • Viral load: > 2x104 IU/mL of HBV DNA
  • HBeAg positive
  • Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
  • Viral load: not exceeding 2x103 IU/mL of HBV DNA
  • HBeAg negative
  • Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
  • Viral load: > 2x103 IU/mL of HBV DNA
  • HBeAg negative
  • Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy

Exclusion Criteria:

  • Any hepatitis B specific treatment prior to blood sampling at Visit 1.
  • Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
  • Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
  • Receipt of blood products within 120 days prior to study entry (Visit 1).
  • Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
  • Receipt of interferon within 120 days prior to study entry (Visit 1).
  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
  • Pregnant or lactating female.
  • History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
  • History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
  • History of major congenital defect.
  • Subjects with a history of, or current, alcohol or substance abuse.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Outro: HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Outro: Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Outro: HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Prazo: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de abril de 2010

Conclusão Primária (Real)

20 de fevereiro de 2012

Conclusão do estudo (Real)

20 de fevereiro de 2012

Datas de inscrição no estudo

Enviado pela primeira vez

1 de abril de 2010

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de abril de 2010

Primeira postagem (Estimativa)

2 de abril de 2010

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de fevereiro de 2020

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de fevereiro de 2020

Última verificação

1 de fevereiro de 2020

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever